Table I.
Comparison of general clinical data between the two groups prior to treatment.
| Group | Cases, n | Age, years | Gender, male, n (%) | Course length, years | Blood glucose, mmol/l | HbA1C, % | BMI, kg/m2 | |
|---|---|---|---|---|---|---|---|---|
|
| ||||||||
| FBG | 2hPBG | |||||||
| Metformin | 47 | 60.1±9.6 | 17 (50) | 7.3 | 8.0±1.6 | 12.82±3.7 | 7.2±2.4 | 24.9±5.8 |
| Pioglitazone | 46 | 60.3±9.7 | 17 (51.5) | 7.2 | 8.1±1.6 | 12.69±3.6 | 7.1±2.5 | 24.6±5.6 |
| P-value | 0.183 | 0.412 | 0.089 | 0.215 | 0.176 | 0.343 | 0.358 | |
BMI, body mass index; HbA1C, glycosylated hemoglobin; FBG, fasting blood glucose; 2hPBG, 2 h postprandial blood glucose.